CD4 and non-small cell lung carcinoma: This trial enrolled patients with stage IV non-small cell lung cancer (NSCLC) that were treated with universal cancer peptide-based vaccine (UCPVax) that is based on human telomerase reverse transcriptase (hTERT) derived-MHC class II peptides capable of eliciting CD4+ Th1 responses24.